Primary chemotherapy in breast cancer

Area of Science:

• Oncology
• Breast Cancer Research
• Chemotherapy

Background:

• Primary (neoadjuvant) chemotherapy is a key treatment modality for early operable breast cancer.
• This approach is rapidly evolving in clinical practice and research.

Purpose of the Study:

• To evaluate the efficacy and impact of primary chemotherapy in early operable breast cancer.
• To assess its role in predicting long-term survival and facilitating personalized treatment selection.

Main Methods:

• Analysis of randomized trials comparing primary chemotherapy with adjuvant chemotherapy.
• Monitoring of tumor response and biological markers during neoadjuvant treatment.

Main Results:

• Significant tumor responses observed in approximately 80% of patients.
• Reduced need for mastectomy in patients with large primary tumors, without increased local recurrence.
• Survival outcomes equivalent to those of adjuvant chemotherapy.

Conclusions:

• Primary chemotherapy is an effective treatment for early operable breast cancer, offering comparable survival to adjuvant therapy.
• Tumor response to primary chemotherapy can predict long-term survival.
• It enables serial biological measurements for personalized treatment and rapid evaluation of novel therapies.